NewEdge Advisors’s BioLineRX BLRX Stock Holding History

NewEdge Advisors’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$256	Sell	82 -25	-23%	-$72	﹤0.01%	4106
2026 Q1	$247	Hold	107	–	–	﹤0.01%	4055
2025 Q4	$296	Hold	107	–	–	﹤0.01%	4113
2025 Q3	$405	Hold	107	–	–	﹤0.01%	3967
2025 Q2	$489	Hold	107	–	–	﹤0.01%	3805
2025 Q1	$317	Sell	107 -1	-0.9%	-$4	﹤0.01%	3764
2024 Q4	$920	Hold	108	–	–	﹤0.01%	3573
2024 Q3	$2.31K	Hold	108	–	–	﹤0.01%	3351
2024 Q2	$2.45K	Hold	108	–	–	﹤0.01%	3295
2024 Q1	$4.82K	Hold	108	–	–	﹤0.01%	3151
2023 Q4	$6.75K	Hold	108	–	–	﹤0.01%	3007
2023 Q3	$7.83K	Hold	108	–	–	﹤0.01%	2660
2023 Q2	$6.86K	Hold	108	–	–	﹤0.01%	2717
2023 Q1	$3.81K	Hold	108	–	–	﹤0.01%	2863
2022 Q4	$3	Buy	+108	New	+$3.21K	﹤0.01%	3881

Other funds holding BLRX

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

BCV

Banque Cantonale Vaudoise Lausanne, Switzerland $722M AUM 30.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

NewEdge Advisors's BLRX Position: Q2 2026 in Review

NewEdge Advisors reduced its BioLineRX (BLRX) stake by 23% in Q2 2026, selling an estimated $72 and leaving 82 shares worth $256. The position accounts for ﹤0.01% of the portfolio, ranked #4106.

NewEdge Advisors first reported a position in BLRX in Q4 2022 and has held it in 15 quarters since. The position peaked at $7.83K in Q3 2023. 9 funds tracked by Wall St. Rank hold BLRX as of Q2 2026.

NewEdge Advisors held 82 shares of BioLineRX worth $256 as of Q2 2026.
NewEdge Advisors sold 25 BioLineRX shares in Q2 2026, an estimated $72.
BioLineRX made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #4106 holding.
NewEdge Advisors first reported a position in BioLineRX in Q4 2022 and has held it in 15 quarters since.
NewEdge Advisors's BioLineRX position peaked at $7.83K in Q3 2023.
9 funds tracked by Wall St. Rank held BioLineRX as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.